BioNTech SE - ADR

NASDAQ:BNTX   11:28:02 AM EDT
135.62
+2.02 (+1.51%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)32.91B
Current PE2.80
Forward PE 4.06
2yr Forward PE 7.56
See more stats
Estimates Current Quarter
Revenue$2.35 Billion
Adjusted EPS$3.62
See more estimates
10-Day MA$134.01
50-Day MA$150.04
200-Day MA$163.25
See more pivots

BioNTech SE - ADR Stock, NASDAQ:BNTX

An der Goldgrube 12, Mainz, Rheinland-Pfalz 55131
Germany
Phone: +49.6131.9084.0
Number of Employees: 3082

Description

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.